Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Bristol-Myers Squibb Company PFD CONV 2
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-95.3% vs price
Base Case (Median)
-93.3% vs price
Bull Case (75th pct.)
-89.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $394.70 | -57.8% | High (40%) |
| PE Comparable | $102.11 | -89.1% | Medium (25%) |
| Growth Trajectory DCF | $62.21 | -93.3% | Medium (20%) |
| Graham Number | $30.49 | -96.7% | Medium (40%) |
| EV/EBITDA | $56.71 | -93.9% | Medium (20%) |
| EV/FCF | $94.33 | -89.9% | Medium (20%) |
| Earnings Power Value | $27.56 | -97.1% | Medium (50%) |
Based on 7 out of 7 methods, BMYMP appears overvalued at the current price of $935.22. The base case fair value of $62.21 implies 93.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.